We therefore decided to investigate the anti-tumor activity of the potent MDM2 inhibitors Idasanutlin and Milademetan, which are currently being tested in clinical trials of p53 wild-type tumors [13], in the p53-mutated TNBC cell lines MDA-MB-231, MDA-MB-436, and MDA-MB-468. This evidence concerns the gene TP53 and neoplasm.